Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C
- PMID: 15816478
Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C
Abstract
Background/aims: Iron-induced oxidative stress plays an important role in the pathogenesis of chronic hepatitis C. Both phlebotomy for removing body iron stores and low iron diet for minimizing portal iron supply to the liver have been shown to improve serum transaminase levels in patients with the disease. However, the cooperative effects of phlebotomy and low iron diet have not yet been elucidated in detail.
Methodology: A pilot study was undertaken to investigate whether a low iron diet could improve the efficacy of phlebotomy in iron reduction therapy. Of 21 patients diagnosed with chronic hepatitis C, 10 patients were treated with phlebotomy alone (group A) while 11 patients were treated with a low iron plus phlebotomy (group B). Phlebotomy was repeated biweekly until serum ferritin levels reached 10 ng/mL in both A and B groups. In addition, a low iron diet (iron intake of 8 mg/day or less) was recommended for group B, followed by estimation of iron intake from daily diet records.
Results: Serum alanine aminotransferase levels were significantly improved from 106+/-30 to 68+/-22 IU/L (p<0.005, paired t-test) in group A and from 100+/-33 to 46+/-10 IU/L (p<0.002, paired t-test) in group B. The enzyme levels after treatment were significantly higher in group A (p<0.02, non-paired t-test), which showed a higher upward distribution of the enzyme activity. The estimated dietary iron intake in group B was reduced from 17.6+/-6.1 to 8.2+/-3.7 mg/day.
Conclusions: These findings suggest that phlebotomy alone does not completely remove iron-induced oxidative stress and a low iron diet induces an additional effect in iron reduction therapy for chronic hepatitis C.
Similar articles
-
Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet.Cancer Res. 2001 Dec 15;61(24):8697-702. Cancer Res. 2001. PMID: 11751387 Clinical Trial.
-
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan.J Gastroenterol. 2004 Jun;39(6):570-4. doi: 10.1007/s00535-003-1344-z. J Gastroenterol. 2004. PMID: 15235875 Clinical Trial.
-
Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.Hepatology. 2000 Mar;31(3):730-6. doi: 10.1002/hep.510310325. Hepatology. 2000. PMID: 10706565 Clinical Trial.
-
Role of iron in the natural history and clinical course of hepatitis C disease.Hepatogastroenterology. 1998 Mar-Apr;45(20):349-55. Hepatogastroenterology. 1998. PMID: 9638405 Review.
-
Therapy of hepatitis C: other options.Hepatology. 1997 Sep;26(3 Suppl 1):143S-151S. doi: 10.1002/hep.510260725. Hepatology. 1997. PMID: 9305680 Review.
Cited by
-
Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort.J Natl Cancer Inst. 2010 Sep 8;102(17):1354-65. doi: 10.1093/jnci/djq301. Epub 2010 Aug 20. J Natl Cancer Inst. 2010. PMID: 20729477 Free PMC article.
-
Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.PLoS One. 2014 Feb 19;9(2):e89355. doi: 10.1371/journal.pone.0089355. eCollection 2014. PLoS One. 2014. PMID: 24586712 Free PMC article.
-
The effect of iron depletion on chronic hepatitis C virus infection.Hepatol Int. 2008 Sep;2(3):335-40. doi: 10.1007/s12072-008-9076-z. Epub 2008 May 8. Hepatol Int. 2008. PMID: 19669262 Free PMC article.
-
Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study.J Gastroenterol. 2007 Jan;42(1):49-55. doi: 10.1007/s00535-006-1967-y. Epub 2007 Feb 16. J Gastroenterol. 2007. PMID: 17322993
-
Genetically determined circulating micronutrients and the risk of nonalcoholic fatty liver disease.Sci Rep. 2024 Jan 11;14(1):1105. doi: 10.1038/s41598-024-51609-3. Sci Rep. 2024. PMID: 38212362 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical